Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 12/20 | 0.43 |
| ▸ | PPARD | Q03181 | 11/20 | 0.43 |
| ▸ | PPARG | P37231 | 9/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098942 | 0.89 | GRM2 (0.55) | NR1H2NR1H3GRM2PPARAPPARD | |
| SCHEMBL6097922 | 0.88 | NR1H2 (0.74) | NR1H2NR1H3GRM2PPARAPPARD | |
| SCHEMBL6098935 | 0.86 | GRM2 (0.52) | NR1H2NR1H3GRM2PPARAPPARD | |
| SCHEMBL6098717 | 0.84 | NR1H2 (0.52) | NR1H2NR1H3GRM2PPARAPPARD | |
| SCHEMBL6100866 | 0.83 | NR1H2 (0.78) | NR1H2NR1H3PPARAPPARDPPARG | |
| SCHEMBL6404754 | 0.83 | NR1H2 (0.48) | NR1H2NR1H3GRM2PPARAPPARD | |
| SCHEMBL6100087 | 0.81 | GRM2 (0.63) | NR1H2NR1H3GRM2PPARAPPARD | |
| SCHEMBL6100301 | 0.81 | NR1H2 (0.61) | NR1H2NR1H3GRM2PPARAPPARD | |
| SCHEMBL6422304 | 0.81 | GRM2 (0.58) | NR1H2NR1H3GRM2PPARAPPARD | |
| SCHEMBL6368217 | 0.80 | GRM2 (0.59) | NR1H2NR1H3GRM2PPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125865-B2 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | claimed |
| US-20050239769-A1 | Therapeutic compounds for treating dyslipidemic conditions | MERCK SHARP & DOHME CORP. | 2005-10-27 | — | — | US | claimed |
| EP-1758651-A2 | LXR AGONISTS TO PROMOTE BONE HOMEOSTASIS | Galapagos N.V. (BE) | 2007-03-07 | — | — | EP | disclosed |
| US-7125865-B2 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | disclosed |
| WO-2006000577-A9 | LXR AGONISTS TO PROMOTE BONE HOMEOSTASIS | GALAPAGOS GENOMICS NV (BE) | 2006-04-20 | — | — | WO | disclosed |
| US-20060020036-A1 | Methods and compositions to promote bone homestasis | GALAPAGOS N.V. (BE) | 2006-01-26 | — | — | US | disclosed |
| WO-2006000577-A2 | LXR AGONISTS TO PROMOTE BONE HOMEOSTASIS | GALAPAGOS N.V. (BE) | 2006-01-05 | — | — | WO | disclosed |
| US-20050239769-A1 | Therapeutic compounds for treating dyslipidemic conditions | MERCK SHARP & DOHME CORP. | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239769-A1 | Therapeutic compounds for treating dyslipidemic conditions | NR1H2, NR1H3, LDLR | NR1H2 1/4885NR1H3 2/4885GRM2 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.